Literature DB >> 30789139

Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007-2016.

Hyewon Lee, Woojae Myung, Won-Jung Koh, Seong Mi Moon, Byung Woo Jhun.   

Abstract

The prevalence and incidence of nontuberculous mycobacterial (NTM) infections increased in South Korea from 2007 to 2016. Annual prevalence of NTM infection increased to 39.6 cases/100,000 population in 2016 and annual incidence to 19.0 cases/100,000 population. Overall prevalence for the study period was higher in the elderly, in females, and in cities.

Entities:  

Keywords:  South Korea; bacteria; epidemiology; mycobacteria; nontuberculous mycobacteria; tuberculosis and other mycobacteria

Mesh:

Year:  2019        PMID: 30789139      PMCID: PMC6390769          DOI: 10.3201/eid2503.181597

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


The prevalence and incidence of nontuberculous mycobacterial (NTM) infection are increasing worldwide (), and it is important to characterize the distribution of NTM infection by demographics or ecologic region to optimize disease control. However, data vary widely by study, and the epidemiology of NTM infection differs among countries. Although the number of patients with NTM infection has increased in South Korea (), representative nationwide population-based epidemiologic data on the extent and distribution of NTM infection are lacking. We evaluated the prevalence, incidence, and spatial distribution of NTM infection in South Korea over a 10-year period, using national health insurance data.

The Study

We based our study on the Health Insurance Review and Assessment Service database, which includes universal health insurance claim data in South Korea. Approximately 97% of the population (≈52 million persons) is included in the system (). We obtained demographic and medical data from the database for 2007–2016. We defined NTM infection as the presence of a diagnostic code associated with NTM infection (International Classification of Diseases, 10th ed., code A31) as either a primary or secondary diagnosis () and claims data for acid-fast bacilli smears or mycobacterial culture. We defined annual prevalence as the number of all patients with NTM infection alive during each year and annual incidence as the number of newly diagnosed NTM infections occurring each year after excluding patients who were diagnosed in a previous study period (e.g., patients diagnosed during 2007–2015 were excluded from the estimate of the 2016 incidence rate). We first calculated the crude prevalence rate and incidence rate using each year’s total population as the denominator. To adjust for different population structures between years, we calculated the age- and sex-standardized annual prevalence rate and incidence rate of NTM disease using the 2005 population as a standard population, based on the Statistics Korea method (http://kostat.go.kr/portal/eng/index.action). First, we calculated the prevalence and incidence rates for age and sex groups by stratifying all NTM cases into the groups and dividing by the group-specific populations in each year. Then, we multiplied each year’s group-specific rates and the group-specific populations in 2005, combined the multiplied values, and divided by the 2005 total population. We calculated standardized overall period prevalence of NTM infection by age, sex, and administrative divisions using the population in the middle of the study period. We conducted statistical analyses using SAS version 9.4 (SAS Institute, http://www.sas.com). Because we used deidentified data in the study, institutional review board approval and patient consent were not required. A total of 33,974 cases of NTM infection were identified during 2007–2016. The age- and sex-adjusted annual prevalence of NTM infection increased by more than 5-fold, from 6.7 cases/100,000 population in 2007 to 39.6 cases/100,000 population in 2016 (Figure 1). The age- and sex-adjusted annual incidence of NTM infection more than tripled, from 6.0 cases/100,000 population/year in 2008 to 19.0 cases/100,000 population/year in 2016. The overall period prevalence of NTM infection increased with patient age (Figure 2, panel A): prevalence was lowest at <19 years of age (1.7 cases/100,000 population), increased dramatically after 50 years of age, and peaked in those 70 years of age (223.0 cases/100,000 population). The overall period prevalence of NTM infection was higher among females in all age groups, except for those >70 years of age (Figure 2, panel B).
Figure 1

Annual prevalence (total no. cases/100,000 population) and incidence (no. new cases/100,000/year) of nontuberculous mycobacterial infection, adjusted for age and sex, South Korea, 2007–2016.

Figure 2

Overall period prevalence (total no. cases/100,000 population) of nontuberculous mycobacterial infection, by age group (A) and by age group and sex (B), South Korea, 2007–2016.

Annual prevalence (total no. cases/100,000 population) and incidence (no. new cases/100,000/year) of nontuberculous mycobacterial infection, adjusted for age and sex, South Korea, 2007–2016. Overall period prevalence (total no. cases/100,000 population) of nontuberculous mycobacterial infection, by age group (A) and by age group and sex (B), South Korea, 2007–2016. In South Korea, the overall period prevalence of NTM infection tended to be higher in metropolitan cities, which had greater population densities and higher income levels, than in the provinces (Table 1). The overall period prevalence exceeded 100 cases/100,000 population in most metropolitan cities (5/7, 71.4%) but did not exceed that rate in most provinces (7/9, 77.8%). The prevalence was highest in Gwangju and in Seoul, the capital of South Korea, both of which had >250 cases/100,000 population. Prevalence was lowest in Cheju, the largest and southernmost island (35.8 cases/100,000 population) (Appendix Figure).
Table 1

Overall prevalence of nontuberculous mycobacterial infections by administrative division, adjusted for age and sex, South Korea, 2007–2016

DistrictNo. infectionsNo. cases/100,000 population
Metropolitan city
Seoul13,671254.5
Busan2,055102.6
Daejeon1,384194.4
Gwangju2,121302.0
Daegu1,642119.9
Incheon1,16986.3
Ulsan
401
81.5
Province
Gyeonggi-do6,195110.2
Gangwon-do1,107108.9
Jeollabuk-do1,21398.4
Jeollanam-do47035.1
Gyeongsangbuk-do49726.8
Gyeongsangnam-do1,20166.0
Chungcheongbuk-do28530.6
Chungcheongnam-do44435.2
Cheju-do (island)11935.8
Analysis of age and underlying conditions indicated that most case-patients (83.4%) were >50 years of age (Table 2). The most frequent underlying respiratory condition was asthma (53.0%), followed by bronchiectasis (43.6%) and chronic obstructive pulmonary disease (COPD) (32.3%). Lung cancer was the most common malignancy (6.3%). Depressive disorder was noted in 23.1% of case-patients.
Table 2

Sex, age, and underlying conditions among patients with nontuberculous mycobacterial infection, South Korea, 2007–2016*

CategoryNo. (%) infections, n = 33,974
Sex
F18,555 (54.6)
M
15,419 (45.4)
Age group, y
<19197 (0.6)
20–29622 (1.8)
30–391,479 (4.4)
40–493,341 (9.8)
50–597,880 (23.2)
60–698,961 (26.4)
>70
11,494 (33.8)
Underlying condition
Asthma18,003 (53.0)
Bronchiectasis14,815 (43.6)
COPD10,969 (32.3)
Interstitial pulmonary diseases1,832 (5.4)
Myocardial infarction1,016 (3.0)
Congestive heart failure3,581 (10.5)
Cerebrovascular disease7,789 (22.9)
Cancer7,808 (23.0)
Lung cancer2,124 (6.3)
Stomach cancer1,336 (3.9)
Colon cancer975 (2.9)
Liver cancer661 (2.0)
Prostate cancer606 (1.8)
Breast cancer577 (1.7)
Uterine cervical cancer126 (0.4)
Thyroid cancer673 (2.0)
Liver disease15,218 (44.8)
Renal disease1,391 (4.1)
Diabetes mellitus11,010 (32.4)
Depressive disorder7,857 (23.1)

*Underlying conditions are listed based on codes from the International Classification of Diseases, 10th edition. COPD, chronic obstructive pulmonary disease.

*Underlying conditions are listed based on codes from the International Classification of Diseases, 10th edition. COPD, chronic obstructive pulmonary disease.

Conclusions

We identified a remarkable increase in the prevalence and incidence of NTM infection in South Korea from 2007 to 2016. The overall period prevalence increased with patient age and was higher in female patients in most age groups. These trends are consistent with previous studies from Europe (), the United States (,), and Japan (,). A representative US study that analyzed Medicare beneficiaries during 1997–2007 revealed that the prevalence of NTM disease increased from 20 to 47 cases/100,000 population and the prevalence was higher among women (). A study conducted in Germany reported an increasing prevalence of NTM disease, from 2.3 cases/100,000 population in 2009 to 3.3 cases/100,000 population in 2014 (). Studies in Japan, which is geographically close to South Korea, showed similar trends, but the rates were higher than those in the United States or Europe. The estimated annual prevalence of NTM disease in Japan in 2005 was 33–65 cases/100,000 population (), and the incidence in 2015 was 14.7 cases/100,000 population (), which were similar to our data. These results suggest that NTM infection is increasing globally, especially in East Asia, and that epidemiologic distribution can be affected by region or ethnicity. In particular, some studies have indicated that people in East Asia are vulnerable to NTM infection (,). Another notable finding in our study was the difference in NTM prevalence by administrative division, which indicates that NTM infection is related to population density and the degree of urbanization. Supporting our data, other studies have attributed NTM infection to environmental exposure (), and recent studies in the United States revealed that areas with high risk for NTM infection had higher population densities or higher education and income levels (,). In South Korea, the population density is highest in metropolitan cities. These data suggest the importance of epidemiologic surveillance in understanding NTM infection. We frequently observed airway diseases in NTM infection in our study. A US study also reported COPD in 41% and bronchiectasis in 37% of NTM patients (), whereas a study in Germany noted COPD or emphysema in 62%–79% of patients (). One study reported mental disorders as concurrent NTM-related conditions (). In our study, depression was also identified in NTM, which might be explained by the burden of COPD (). These data suggest that an assessment of underlying disease is needed in managing NTM infection. Our study had some limitations. First, because we used diagnosis codes, the distinction between pulmonary and other diseases is unclear, and we could not confirm whether the patients completely met the diagnostic criteria of NTM infection. Second, because we only have data for 2007–2016, we could not exclude patients who had received diagnoses before 2007 when estimating the annual incidence rate. Finally, our definition of NTM infection on the basis of the International Classification of Diseases code may have underestimated the true disease prevalence (,) because prevalence could be affected by loss to follow-up or death during the study period. In conclusion, we report a substantial increasing trend in the prevalence and incidence of NTM infection in South Korea during 2007–2016 and evaluated regional variations. These data facilitate a better understanding of the epidemiologic trends of NTM infection globally.

Appendix

Additional information about nontuberculous mycobacterial infection in South Korea.
  15 in total

1.  Spatial clusters of nontuberculous mycobacterial lung disease in the United States.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Joseph O Falkinham; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-07-05       Impact factor: 21.405

2.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

3.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

Authors:  Kenneth N Olivier; David J Weber; Richard J Wallace; Ali R Faiz; Ji-Hyun Lee; Yansheng Zhang; Barbara A Brown-Elliot; Allison Handler; Rebecca W Wilson; Michael S Schechter; Lloyd J Edwards; Subha Chakraborti; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

4.  Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.

Authors:  Emily Henkle; Katrina Hedberg; Sean Schafer; Shannon Novosad; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2015-05

Review 5.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.

Authors:  D Rebecca Prevots; Theodore K Marras
Journal:  Clin Chest Med       Date:  2014-11-06       Impact factor: 2.878

Review 6.  Depression and anxiety in patients with COPD.

Authors:  Abebaw M Yohannes; George S Alexopoulos
Journal:  Eur Respir Rev       Date:  2014-09

7.  A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan.

Authors:  Kozo Morimoto; Kazuro Iwai; Kazuhiro Uchimura; Masao Okumura; Takashi Yoshiyama; Kozo Yoshimori; Hideo Ogata; Atsuyuki Kurashima; Akihiko Gemma; Shoji Kudoh
Journal:  Ann Am Thorac Soc       Date:  2014-01

8.  Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study.

Authors:  Mehdi Mirsaeidi; Roberto F Machado; Joe G N Garcia; Dean E Schraufnagel
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

9.  Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA.

Authors:  Jennifer Adjemian; Timothy B Frankland; Yihe G Daida; Jennifer R Honda; Kenneth N Olivier; Adrian Zelazny; Stacey Honda; D Rebecca Prevots
Journal:  Emerg Infect Dis       Date:  2017-03       Impact factor: 6.883

10.  Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea.

Authors:  Sang Cheol Seong; Yeon-Yong Kim; Young-Ho Khang; Jong Heon Park; Hee-Jin Kang; Heeyoung Lee; Cheol-Ho Do; Jong-Sun Song; Ji Hyon Bang; Seongjun Ha; Eun-Joo Lee; Soon Ae Shin
Journal:  Int J Epidemiol       Date:  2017-06-01       Impact factor: 7.196

View more
  39 in total

1.  In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Su-Young Kim; Hee Jae Huh; Nam Yong Lee; Won-Jung Koh; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

2.  Pulmonary mycobacterial infection is associated with increased mortality in patients with acute respiratory distress syndrome.

Authors:  Jong Hwan Jeong; Manbong Heo; Sunmi Ju; Seung Jun Lee; Yu Ji Cho; Yi Yeong Jeong; Jong Deog Lee; Jung-Wan Yoo
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

3.  Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease.

Authors:  Sae Rom Kim; Myunghwa Jang; Su-Young Kim; Dae Hun Kim; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2022-09-27       Impact factor: 5.938

4.  The Association Between Bacille Calmette-Guérin Vaccination and Nontuberculous Mycobacterial Pulmonary Disease.

Authors:  Nakwon Kwak; Ha Won Hwang; Hyung-Jun Kim; Hyun Woo Lee; Jae-Joon Yim; Chang-Hoon Lee
Journal:  J Korean Med Sci       Date:  2022-07-04       Impact factor: 5.354

5.  Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease.

Authors:  Joong-Yub Kim; Na Young Kim; Hee-Won Jung; Jae-Joon Yim; Nakwon Kwak
Journal:  BMC Pulm Med       Date:  2022-07-14       Impact factor: 3.320

6.  Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.

Authors:  Seong Mi Moon; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Nam Yong Lee; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2022-03-10       Impact factor: 5.938

Review 7.  Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.

Authors:  Marisa Cruz-Aguilar; Antonia I Castillo-Rodal; René Arredondo-Hernández; Yolanda López-Vidal
Journal:  Scand J Immunol       Date:  2021-06-22       Impact factor: 3.889

8.  Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study.

Authors:  Nakwon Kwak; Sung A Kim; Sun Mi Choi; Jinwoo Lee; Chang-Hoon Lee; Jae-Joon Yim
Journal:  BMC Pulm Med       Date:  2020-05-07       Impact factor: 3.317

9.  Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease.

Authors:  Goh Tanaka; Taisuke Jo; Hiroyuki Tamiya; Yukiyo Sakamoto; Wakae Hasegawa; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Takahide Nagase
Journal:  BMC Infect Dis       Date:  2021-07-20       Impact factor: 3.090

10.  Prevalence of nontuberculous mycobacteria in a tertiary hospital in Beijing, China, January 2013 to December 2018.

Authors:  Jing-Jing Huang; Ying-Xing Li; Ying Zhao; Wen-Hang Yang; Meng Xiao; Timothy Kudinha; Ying-Chun Xu
Journal:  BMC Microbiol       Date:  2020-06-12       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.